Efficacy and Safety Study of Escitalopram Augmentation in Treatment Resistant Schizophrenia
Status:
Completed
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
A primary hypothesis to be explored here is that, given its pharmacodynamic profile and
hypothesized mechanisms associated with schizophrenia, escitalopram will, in comparison to
placebo, be effective when added to risperidone or olanzapine treated group in reducing the
severity of resistant symptoms, particularly existing subsyndromal anxiety and depression.